The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets

@article{Bambico2008TheCC,
  title={The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets},
  author={F. Bambico and G. Gobbi},
  journal={Expert Opinion on Therapeutic Targets},
  year={2008},
  volume={12},
  pages={1347 - 1366}
}
  • F. Bambico, G. Gobbi
  • Published 2008
  • Biology
  • Expert Opinion on Therapeutic Targets
  • Background: Major depression has the highest rate of prevalence and incidence of morbidity among all mental disoders. The limited efficacies of current antidepressant treatments necessitate the development of alternative pharmacotherapies. Recent preclinical findings suggesting that cannabinoid CB1 receptor agonists and endocannabinoid enhancers possess antidepressant-like properties, and clinical evidence that the CB1 antagonist rimonabant increases the risk of depression and suicidality… CONTINUE READING
    Endocannabinoids in the treatment of mood disorders: evidence from animal models.
    • 77
    Endocannabinoids and stress
    • 94

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 195 REFERENCES
    A possible role for the endocannabinoid system in the neurobiology of depression
    • 50
    • PDF
    Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
    • 161
    Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
    • 584
    • PDF
    Cannabis and the brain.
    • 623
    • PDF
    New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia.
    • 86
    • PDF